An interventional study of SELUTION SLR™ (Sustained Limus Release) drug eluting balloon (DEB) in Peripheral Artery Disease, sponsored by M.A. Med Alliance S.A.. Active, not recruiting at 27 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-06.
Sponsored by M.A. Med Alliance S.A. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 173 studies in Peripheral Arterial Disease with a site in Germany — 15 open to participants now, 29 under way, 3 of them phase 3. Peripheral Arterial Disease · Germany.
Among the 173 studies in Peripheral Arterial Disease with a site in Germany, this one is the 13th largest by enrollment of the 126 interventional ones that give a count, is one of 13 that started in 2021, is one of 85 with no phase, reaches primary completion later than 7 of the 28 other live ones, and was the 131st registered.
1,378 studies on the registry are indexed under Peripheral Arterial Disease; 276 are open to participants now.
Browse Peripheral Arterial Disease studies →15 of the 173 studies in Peripheral Arterial Disease with a site in Germany are open now. Recruiting first, the newest first:
W.L.Gore & Associates · Sites in Germany
Ages 18+
University Hospital, Essen · Sites in Germany
Ages 18–85
Biotronik AG · Sites in Germany, Austria, Belgium and 5 more countries
Ages 18+
CSL Behring · Sites in Germany, United States, Argentina and 32 more countries
Ages 18+
University of Leipzig · Sites in Germany
Ages 18+
A study can be open while its sites in Germany have not opened yet or have stopped. Only those recruiting at a site in Germany →
Of the 193 Peripheral Arterial Disease studies recruiting now, 139 (72%) set no upper age limit and 9 (5%) stop at 75 or younger; 13 take children under 18; 19 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
173 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 18 · Phase 3 19 · Phase 4 5
First in 2001; this study’s year is marked. 13 started in 2021.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 723 is above the median of 70 across 927 interventional studies indexed under Peripheral Arterial Disease.
Median enrollment 107 across the 126 interventional studies, 200 across the 47 observational. Of the 118 that completed or were terminated, 34 (29%) have results posted.
This tab as a report to print or save as PDF → With an account.
113 of 173 have an industry lead sponsor. The 10 most frequent:
M.A. Med Alliance S.A. is the lead sponsor of 8 studies on the registry; 1 is open to participants now.
M.A. Med Alliance S.A. has 4 studies filed under Peripheral Arterial Disease — fewer than ten, so there is no comparison to draw.
4 of the studies in Peripheral Arterial Disease with a site in Germany that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04971772Cardionovum GmbHSIGNATURE Study : DCB (Legflow) vs POBA in Fempop Arteries | 2026-12 |
| NCT04110327Micro Medical Solution, Inc.An All-Comers Observational Study of the MicroStent™ Peripheral Vascular Stent System in Subjects With Peripheral Arterial Disease | 2026-12-31 |
| NCT06832631OrbusNeichVITUS Post-Market Registry | 2027-06 |
| NCT05055297M.A. Med Alliance S.A.SELUTION4BTK Trial | 2027-06-01 |
Add all 4 to your calendar (.ics) → With an account.
Among the 173 studies in Peripheral Arterial Disease with a site in Germany, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Open label, real-world, prospective, multi-center, single arm, post-market surveillance study of the SELUTION SLR™ (Sustained Limus Release) drug eluting balloon (DEB).
Open label, real-world, prospective, multi-center, single arm, post-market surveillance study of the SELUTION SLR™ (Sustained Limus Release) drug eluting balloon (DEB).
This study will capture data from the use of the SELUTION SLR according to its approved labelling. Each indication for use will have a specific data sets in addition to generic data sets that are common across all indications.
Patients will be followed for 5 years post-procedure to obtain safety and efficacy data. A health economic analysis will be made comparing data between countries within the study and to published data for existing treatment options. Generic and disease specific Patient Reported Outcome Measures (PROMs) will be used to measure the impact of the intervention on the overall health status of patients.
Imaging data collection for patients whose standard of care includes imaging follow-up will be captured and analysed.
Data will be collected from any subject who receives a CE marked device for treatment of a peripheral (i.e. non-cardiovascular) vascular lesion.
Data analysis will be stratified by lesion location.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Med Alliance SELUTION SLR™ 018 DEB Sirolimus Eluting Balloon Catheter.
Device: SELUTION SLR™ (Sustained Limus Release) drug eluting balloon (DEB)
This study will capture data from the use of the SELUTION SLR according to its approved labelling.
Clinically Driven Target Lesion Revascularization
The primary endpoint will be freedom from Clinically Driven Target Lesion Revascularisation (CD-TLR) at 1-year post-intervention.
Time frame: 1 year after treatment
Device Success
Successful delivery, balloon inflation, deflation and retrieval of the intact study device without burst below rated burst pressure.
Time frame: At end of procedure
Procedure success
Device success and residual stenosis ≤50% at the end of the procedure.
Time frame: At end of procedure
Clinical success
Procedural success without procedural complications (death, major target limb amputation, thrombosis of the target lesion or TLR) prior to discharge.
Time frame: At discharge after procedure
Major Adverse Limb Events (MALE) composite endpoint
Severe limb ischemia leading to an intervention or major vascular amputation (above the ankle).
Time frame: At discharge after procedure and 1, 6, 12, 24, 36, 48 and 60 months
Major Cardiac Events Major Cardiac Events
MI, Stroke, Cardiovascular death
Time frame: At 1, 6, 12, 24, 36,48, 60 months
Death
All-cause, cardiac, device related, procedure related
Time frame: At 1, 6, 12, 24, 36, 48, 60 months
TLR
Number of Target Lesion Revascularizations
Time frame: At 1, 6, 12, 24, 36, 48, 60 months
TVR
Number of Target Vessel Revascularizations
Time frame: At 1, 6, 12, 24, 36, 48, 60 months
Time to first CD-TLR
Time to first Clinically Driven Target Lesion Revascularization
Time frame: up to 60 months
Target limb revascularization
Number of Target limb revascularizations
Time frame: At 1, 6, 12, 24, 36, 48, 60 months
Thrombosis at the target site
Number of Thrombosis at the target site
Time frame: At 1 month
Amputation
Number of Amputations
Time frame: up to 60 months
Rutherford Classification score
Change in Rutherford Classification score from baseline (Scale from 0 to 6, higher score means worse outcome.
Time frame: At 6, 12, 24, 36, 48, 60 months
Ankle Brachial Index (ABI)
Change in ankle brachial index (ABI) from baseline
Time frame: At 6, 12 months only
Pedal pulse
Presence of Pedal pulse
Time frame: 6, 12 months only
Wound status if applicable
location, size, infection, status, Wound, Ischemia and Foot Infection (WIfI) classification system score
Time frame: 6, 12 months only
Kawarada Classification score
Change from baseline to end of procedure to assess change in severity of Pedal Artery Disease
Time frame: At end of procedure
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Feb 2021 to primary completion in Nov 2024, 45 months.
Of 125 industry-sponsored interventional studies with no phase under Peripheral Arterial Disease, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 45. This study's 45 months is above that.
Counting every sponsor, half of 386 studies reached it within 31 months; a quarter within 17 and three quarters within 55.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
M.A. Med Alliance S.A.